Cytori Therapeutics, Inc. (USA) (NASDAQ:CYTX)

CAPS Rating: 2 out of 5

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.

Recs

3
Player Avatar NeroSagetrade (90.89) Submitted: 2/12/2008 3:41:03 AM : Underperform Start Price: $5.61 CYTX Score: +129.91

What a staggeringly STAGGERINGLY bad company! The numbers are absolutely obstrusive. These guys could write a book on how to lose money and it would be a best seller. Cytori has lost a whopping 52M in the last 2 years and is sitting on less than 30M cash again which will not even get them through 2008. Revenues are increasing but at a far too anemic pace to keep the stock at these levels. The book value is a heartbeat from being negative, they are at 11 times sales and will never produce a profit as far as im concerned. Perhaps we need to work on a regenerative cell that gets rid of bad companies like this one and replaces it with good biotech companies that don't waste 25-30M a year. Take the women and children outside..look away, its hideous.

Nero
Sagetrade

Report this Post 2 Replies
Member Avatar JGGardner (< 20) Submitted: 8/3/2010 1:27:08 AM
Recs: 0

This post is over two years old. Motley is looking like a fool.

Member Avatar zzlangerhans (99.78) Submitted: 3/24/2012 2:07:24 AM
Recs: 0

Now it's four years old, and looking very prescient.

Featured Broker Partners


Advertisement